Literature DB >> 28929598

Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.

Sakiko Nanjo1, Sawako Minami1, Mika Mizoguchi1, Madoka Yamamoto1, Tamaki Yahata1, Saori Toujima1, Michihisa Shiro1, Aya Kobayashi1, Yasuteru Muragaki2, Kazuhiko Ino1.   

Abstract

AIM: We aimed to investigate maternal serum angiogenic marker profiles within 1 week prior to delivery in cases of gestational hypertension (GH), pre-eclampsia (PE), and/or fetal growth restriction (FGR) with different clinical conditions.
METHODS: We enrolled 165 women with singleton pregnancy. The participants were classified based on three characteristics: (i) proteinuria (GH and PE); (ii) FGR (PE with FGR [PE + FGR], PE alone, and FGR alone); and (iii) onset (early onset PE [EO PE] and late-onset PE [LO PE]). All sera were obtained within 1 week prior to delivery, and soluble fms-like tyrosine kinase 1 (sFlt-1), soluble endoglin (sEng), and placental growth factor (PlGF) were measured with enzyme-linked immunosorbent assay.
RESULTS: (i) In PE, a significantly increased sFlt-1, sEng, and sFlt-1 to PlGF ratio (sFlt-1/PlGF) and significantly decreased PlGF were observed compared with GH and Term control, whereas in GH, only sFlt-1/PlGF was significantly higher than Term control. (ii) In PE + FGR, similar changes were more markedly shown compared with PE alone. The FGR alone group exhibited similar tendencies as PE, although significant differences were found in PlGF and sEng levels. (iii) In EO PE, significant changes were observed in all factors compared with LO PE or Term control, while no significant change in PlGF levels was observed between LO PE and Term control.
CONCLUSION: We demonstrated that the levels of circulating angiogenic factors just before delivery are correlated with the severity of hypertensive disorders of pregnancy and FGR. Profiling these specific markers may contribute to better understanding of the clinical conditions in individual patients and their pathogenesis.
© 2017 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  fetal growth restriction; placental growth factor; pre-eclampsia; soluble endoglin; soluble fms-like tyrosine kinase 1

Mesh:

Substances:

Year:  2017        PMID: 28929598     DOI: 10.1111/jog.13452

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  5 in total

Review 1.  Placental Syndromes-A New Paradigm in Perinatology.

Authors:  Katarzyna Kosińska-Kaczyńska
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

2.  Assessment of the SFlt-1 and sFlt-1/25(OH)D Ratio as a Diagnostic Tool in Gestational Hypertension (GH), Preeclampsia (PE), and Gestational Diabetes Mellitus (GDM).

Authors:  Malgorzata Walentowicz-Sadlecka; Piotr Domaracki; Pawel Sadlecki; Joanna Siodmiak; Marek Grabiec; Pawel Walentowicz; Maria Teresa Arias Moliz; Grazyna Odrowaz-Sypniewska
Journal:  Dis Markers       Date:  2019-08-06       Impact factor: 3.434

3.  Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus.

Authors:  Anna Maria Nuzzo; Domenica Giuffrida; Laura Moretti; Paola Re; Giorgio Grassi; Guido Menato; Alessandro Rolfo
Journal:  Sci Rep       Date:  2021-01-27       Impact factor: 4.379

4.  Fetal growth restriction as the initial finding of preeclampsia is a clinical predictor of maternal and neonatal prognoses: a single-center retrospective study.

Authors:  Masaya Takahashi; Shintaro Makino; Kyoko Oguma; Haruka Imai; Ai Takamizu; Akari Koizumi; Koyo Yoshida
Journal:  BMC Pregnancy Childbirth       Date:  2021-10-06       Impact factor: 3.007

5.  Bronchopulmonary dysplasia in neonates born to mothers with preeclampsia: Impact of small for gestational age.

Authors:  Pauline Dravet-Gounot; Héloïse Torchin; François Goffinet; Marie-Stéphanie Aubelle; Mayass El Ayoubi; Claire Lefevre; Pierre-Henri Jarreau; Elodie Zana-Taïeb
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.